DeveloGen AG is a biology driven drug discovery company. We are active in the research and development of innovative treatments for type 1 diabetes as well as for type 2 diabetes, obesity and metabolic syndrome. DeveloGen has a deep clinical and preclinical pipeline of projects focused on metabolic diseases.
Type 2 diabetes, obesity and metabolic syndrome are multifactorial diseases, which call for innovative approaches for the identification of novel drug targets. DeveloGen carries out 'phenotype-firs' screens for disease specific targets. Model organisms with metabolic phenotypes are generated via large scale genomewide mutagenesis. To date, the phenotype-first genomic screen has yielded over 200 primary candidates and more than 30 validated targets.
In 2003, DeveloGen entered into a drug discovery partnership with Evotec OAI in the metabolic disease program. The partnership creates an integrated venture combining the best of biology and chemistry.
- pipeline of targets
- assay development
- know-how in pharmacology and metabolic diseases
Evotec OAI contributes:
- medicinal chemistry
- drug manufacture
Four drug discovery projects are currently ongoing with a team of over 50 scientists from both companies. The goal of the partnership is to discover potent and promising product candidates for the treatment of metabolic disease.